Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121825) titled 'A multicenter, single-arm phase II clinical study of eribulin combined with inituzumab and pyrotinib in the treatment of HER2-positive advanced breast cancer' on April 3.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
Condition:
breast cancer
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2026-03-18
Target Sample Size: Test group:76;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=312570
Published by HT Digital Content Services with permission from Heal...